A Rapid Screening Program for Histoplasmosis, Tuberculosis, and Cryptococcosis Reduces Mortality in HIV Patients from Guatemala

• Published in: Journal of fungi (Basel) Vol. 7; no. 4; p. 268
• Main Authors: Medina, Narda, Alastruey-Izquierdo, Ana, Bonilla, Oscar, Gamboa, Osmar, Mercado, Danicela, Pérez, Juan C, Salazar, Luis Roberto, Arathoon, Eduardo, Denning, David W, Rodriguez-Tudela, Juan Luis
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-04-2021; MDPI
• Subjects: Acquired immune deficiency syndrome; AIDS; Amphotericin B; Antigens; CD4 antigen; Cryptococcosis; Drug therapy; Flucytosine; Histoplasmosis; HIV; Human immunodeficiency virus; Infections; Laboratories; laboratory diagnosis; Minority & ethnic groups; Mortality; opportunistic infections; Rural areas; Tuberculosis; Urine; Guatemala; United States > US; Oklahoma; opportunistic infections; laboratory diagnosis; histoplasmosis; cryptococcosis; tuberculosis
• ISSN: 2309-608X; 2309-608X
• DOI: 10.3390/jof7040268

Opportunistic infections (OIs) and advanced HIV disease (AHD) contribute to HIV-related mortality. Here, we analyzed the situation of AHD and OIs in a cohort of newly diagnosed HIV patients from Guatemala. We included 2127 adult patients from 13 facilities across the country during 2017 to 2018. Patients were screened for tuberculosis (TB), nontuberculous mycobacteria (NTM), histoplasmosis, and cryptococcal disease, independently of their CD4 cell count. Of the 2127 enrolled patients, 1682 (79.1%) had a CD4 cell count available; of which 52% presented with AHD. Of the Mayan population, 65% had AHD. The overall OI incidence was 21%. Histoplasmosis was the most frequent OI (7.9%), followed by TB (7.1%); 94.4% of these infections occurred in patients with a CD4 < 350 cells/mm
. Mortality at 180 days was significantly higher in those with OIs than without OIs (29.7% vs. 5.9%,
< 0.0001). In one year, this program decreased the OI mortality by 7% and increased the OI treatment by 5.1%. Early OI diagnosis and appropriate therapy reduced OI mortality among newly diagnosed HIV patients in Guatemala. Screening for OIs should be considered in all newly diagnosed HIV patients who have a CD4 cell count < 350 cells/mm
or those without a CD4 cell count available. To improve results, interventions such as early HIV detection and access to flucytosine and liposomal amphotericin B are required.